The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of immune checkpoint inhibitors (ICIs) in rare histological variants of bladder cancer.
 
Errol James Philip
No Relationships to Disclose
 
Francis Wright
Employment - Kaiser Permanente (I)
 
Daniel Myung Kim
No Relationships to Disclose
 
Daniel Kwon
No Relationships to Disclose
 
Hansen Ho
Stock and Other Ownership Interests - UnitedHealthcare
Honoraria - Clovis Oncology
Travel, Accommodations, Expenses - Clovis Oncology
 
Son Ho
No Relationships to Disclose
 
Edna Cheung
No Relationships to Disclose
 
Emily Chan
Research Funding - Proscia (Inst)
 
Sima P. Porten
Honoraria - photocure
Consulting or Advisory Role - Bristol-Myers Squibb; Photocure
Research Funding - Photocure (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Anthony C. Wong
No Relationships to Disclose
 
Hala Borno
Employment - Collective Health (I)
Leadership - Collective Health (I)
Stock and Other Ownership Interests - Collective Health (I)
 
Arpita Desai
No Relationships to Disclose
 
Jonathan Chou
Stock and Other Ownership Interests - Array BioPharma (I); Atara Biotherapeutics (I); Celgene (I)
 
David Yoonsuk Oh
Consulting or Advisory Role - Maze Therapeutics
Research Funding - Merck; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Inventor on patent claiming methods for the use and optimization of cytotoxic CD4+ T cell therapy for cancer.; Inventor on patent claiming methods to identify patients who will respond to or experience toxicity with cancer immunotherapies based on T cell receptor sequencing.
Travel, Accommodations, Expenses - Roche/Genentech
 
Rahul Raj Aggarwal
Honoraria - Clovis Oncology
Consulting or Advisory Role - AstraZeneca; Janssen
Research Funding - Abbvie; Cancer Targeted Technology; Janssen; Merck; Novartis; Xynomic Pharma; Zenith Epigenetics
Travel, Accommodations, Expenses - Xynomic Pharma
 
Lawrence Fong
Consulting or Advisory Role - Atreca; BioAtla; Bolt Biotherapeutics; Nutcracker Therapeutics, Inc.; TeneoBio
Research Funding - Abbvie (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Eric Jay Small
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics
Honoraria - Janssen
Consulting or Advisory Role - Beigene; Fortis; Janssen Oncology; Tolero Pharmaceuticals
Research Funding - Janssen (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Janssen
 
Terence W. Friedlander
Leadership - Med BioGene
Honoraria - AstraZeneca/MedImmune; EMD Serono
Consulting or Advisory Role - Abbvie; Abbvie; AstraZeneca; Foundation Medicine; Janssen; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Janssen; Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Genentech/Roche; Jounce Therapeutics
 
Vadim S Koshkin
Consulting or Advisory Role - Janssen